Biogen shutters digital health group, ends Apple study, in cost cutting move

RubyWallauforSTATBiogen,theiconicbutembattledbiotechfirm,isshutteringBiogenDigitalHealth,itsroughly1 OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand




fashion

author：comprehensive    Page View：413
Michel Pairet -- health business coverage from STAT
Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline. 

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar. 

advertisement

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： How one patient went off dialysis — and others can too
Next article： United colonoscopy coverage change 'may cost lives,' doctors say